Patents by Inventor Mickaël FER

Mickaël FER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066027
    Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of pain, an autoimmune disorder, an autoinflammatory disorder, an inflammatory disorder, a central nervous system disorder, spinal cord injury, a metabolic disorder, a gastrointestinal disorder, a cardiovascular disorder, a fibrotic disorder, a respiratory disorder, a skin disorder, an allergic disorder, or cancer.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 29, 2024
    Inventors: Stanislas MAYER, Anne-Laure BLAYO, Mickaël FER, Anaïs BARRÉ, Mathieu MICHAUT, Gaël HOMMET, Stephan SCHANN, Baptiste RUGERI
  • Publication number: 20220298135
    Abstract: The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction.
    Type: Application
    Filed: August 6, 2020
    Publication date: September 22, 2022
    Applicant: Domain Therapeutics
    Inventors: Stephan SCHANN, Mickaël FER, Stanislas MAYER, Christelle DOEBELIN
  • Publication number: 20210361669
    Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
    Type: Application
    Filed: October 22, 2019
    Publication date: November 25, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Anne-Laure BLAYO, Bapriste MANTEAU, Camille AMALRIC, Stanislas MAYER, Stehan SCHANN, Mickaël FER